Spots Global Cancer Trial Database for ntrk2
Every month we try and update this database with for ntrk2 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | NCT02568267 | Breast Cancer Cholangiocarcin... Colorectal Canc... Head and Neck N... Lymphoma, Large... Melanoma Neuroendocrine ... Non-Small Cell ... Ovarian Cancer Pancreatic Canc... Papillary Thyro... Primary Brain T... Renal Cell Carc... Sarcomas Salivary Gland ... Adult Solid Tum... | Entrectinib | 18 Years - | Hoffmann-La Roche | |
| Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | NCT02920996 | Carcinoma, Non-... Solid Tumor | Merestinib | 18 Years - | Dana-Farber Cancer Institute | |
| Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | NCT02920996 | Carcinoma, Non-... Solid Tumor | Merestinib | 18 Years - | Dana-Farber Cancer Institute | |
| A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer | NCT02122913 | Solid Tumors Ha... | Larotrectinib (... | 18 Years - | Bayer | |
| Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion | NCT03025360 | Tumors Harborin... | Larotrectinib (... | - | Bayer | |
| Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors | NCT03182257 | Solid Tumor | ONO-7579 | 18 Years - | Ono Pharmaceutical Co. Ltd | |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | NCT02650401 | Solid Tumors CNS Tumors | Entrectinib | 0 Years - 18 Years | Hoffmann-La Roche | |
| A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | NCT02576431 | Solid Tumors Ha... | BAY2757556 (Lar... | 18 Years - | Bayer | |
| A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer | NCT03215511 | Solid Tumors Ha... | Selitrectinib (... | 1 Month - | Bayer | |
| Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion | NCT03206931 | Solid Tumors Ha... | Selitrectinib (... | 1 Month - | Bayer | |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | NCT02650401 | Solid Tumors CNS Tumors | Entrectinib | 0 Years - 18 Years | Hoffmann-La Roche | |
| Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors | NCT03182257 | Solid Tumor | ONO-7579 | 18 Years - | Ono Pharmaceutical Co. Ltd |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
